Triple-Negative Breast Cancer | Clinical Trials | Oropharyngeal Cancer, Cancer Information Highlights, 05/26/2021

Having trouble viewing this email? View it as a Web page.

Cancer Information Highlights From the National Cancer Institute Updating you about cancer causes, prevention, screening, treatment, coping, and more   New from NCI Targeted Therapy Approved for Triple-Negative Breast Cancer   The Food and Drug Administration (FDA) has fully approved sacituzumab govitecan (Trodelvy) for some people with triple-negative breast cancer. Sacituzumab consists of an antibody coupled to the chemotherapy drug irinotecan (Camptosar). The antibody binds to breast cancer cells, bringing the chemotherapy to those cells. Clinical Trials Help Build the Future of Medicine   Read how Dr. Raymond Osarogiagbon helps people in Memphis find cancer treatment options through clinical trials and how Dr. Linda Robertson, Patty Andres-Sanmartin, and CeCe Williams help Pittsburgh's underserved patients navigate cancer. Looking for Ways to Do Less Harm When Treating Oropharyngeal Cancer Learn more about oropharyngeal cancer, a type of head and neck cancer, and efforts to treat it with less intense treatment. Usual treatments for this cancer often cause severe side effects. Discovery of Tumor Suppressor Suggests New Ways To Treat Cancer Researchers have shown that the loss of a protein called AMBRA1 can cause tumors to form in mice and is linked with worse outcomes in some people with cancer. The loss of AMBRA1 also reduces how well certain drugs work on the tumors, so new research could lead to better treatment strategies. PDQ Updates Malignant Mesothelioma We've revised our malignant mesothelioma summary with updated information about treatment for stages II, III, and IV disease. FDA Approvals New Treatment for Non-Hodgkin Lymphoma We've added a new drug summary for loncastuximab tesirine-lpyl (Zynlonta). This drug was recently approved by FDA to treat adults with certain types of B-cell non-Hodgkin lymphoma that came back or did not get better after other treatment.   Also of Interest NCI's Clinical Trials Programs Learn why clinical trials are vital to making progress against cancer, how new knowledge about cancer is changing clinical trials, and how NCI programs make a difference. Time to Be Smokefree Smokefree.gov offers science-based tools and support to help smokers quit. It includes links to tailored information for veterans, women, teens, Spanish-speakers, and people over 60 who want to be smokefree. Contact Us for Help Information specialists at NCI's Cancer Information Service (CIS), NCI's contact center, are available to help answer your cancer-related questions in English and Spanish. Reach us by phone, chat, or email.

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp       Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Help

 

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892